Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024)
Invivyd (IVVD) reported Total Non-Current Liabilities of $62.0 million for Q4 2024, up 21.49% on a YoY basis from $51.0 million in Q1 2024, and down 21.31% quarter-over-quarter from $78.8 million in Q3 2024.
Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Invivyd has reported Total Non-Current Liabilities for 5 years, with the latest figure at $62.0 million in Q4 2024.
- For the quarter ending Q4 2024, Total Non-Current Liabilities rose 21.49% year-over-year to $62.0 million; the trailing twelve-month figure through Dec 2024 stood at $62.0 million (up 21.49% YoY), and the FY2024 full-year result was $62.0 million, up 21.49% from the prior year.
- Total Non-Current Liabilities for Q4 2024 stood at $62.0 million, down from $78.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $96.9 million in Q1 2022, with the low at $13.1 million in Q4 2020.
- Historically, Total Non-Current Liabilities has averaged $50.8 million across 5 years, with a median of $49.2 million in 2022.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 374.4% — and 2022, when it sank 56.18%.
- Invivyd's Total Non-Current Liabilities stood at $13.1 million in 2020, then jumped by 374.4% to $62.1 million in 2021, then sank by 56.18% to $27.2 million in 2022, then surged by 87.57% to $51.0 million in 2023, then grew by 21.49% to $62.0 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $62.0 million (Q4 2024), $78.8 million (Q3 2024), and $36.7 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 61.98 Mn |
| Sep 30, 2024 | 78.76 Mn |
| Jun 30, 2024 | 36.70 Mn |
| Mar 31, 2024 | 36.97 Mn |
| Dec 31, 2023 | 51.01 Mn |
| Sep 30, 2023 | 27.72 Mn |
| Dec 31, 2022 | 27.20 Mn |
| Sep 30, 2022 | 47.30 Mn |
| Jun 30, 2022 | 69.77 Mn |
| Mar 31, 2022 | 96.88 Mn |
| Dec 31, 2021 | 62.07 Mn |
| Dec 31, 2020 | 13.08 Mn |